[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tachycardia-atrial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tachycardia-atrial":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100545055",false,"NCT06376916","Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR","Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR","ATRIUM","Inclusion Criteria:\n\n* Age \\> 18 years or older\n* Able to provide informed consent\n* Primary diagnosis AFF RVR greater than or equal to 120 bpm\n* Diltiazem as rate control agent\n* English speaking\n\nExclusion Criteria:\n\n* Hemodynamically unstable patients (SBP \\\u003C90, MAP \\\u003C65)\n* Impaired consciousness\n* End stage renal disease on hemodialysis or peritoneal dialysis\n* Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and\u002For additional imaging\n* Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis\n* Rhythms other than AF, such as sick sinus syndrome or wide-complex ventricular response\n* Acute myocardial infarction\n* Pregnancy defined as a positive urine HCG (human chorionic gonadotropin)\n* Contraindications to magnesium sulfate (including myasthenia gravis)\n* Allergy or sensitivity to any study drugs\n* Previously enrolled in this trial during a different patient encounter\n* Withdrew from study","ALL","18 Years",{"count":19,"type":20},153,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.",[26,27,28],"Tachycardia Atrial","Atrial Fibrillation","Atrial Flutter With Rapid Ventricular Response","RECRUITING","2025-10-25",{"date":32,"type":33},"2025-10-28","ACTUAL",{"date":35,"type":33},"2024-10-07",{"date":37,"type":20},"2026-12",{"name":39,"class":40},"Wake Forest University Health Sciences","OTHER",""]